Human hemin is a medication used for the treatment of acute intermittent porphyria, a rare metabolic disorder caused by an enzymatic deficiency in heme synthesis. It helps reduce the production of toxic precursors that cause the symptoms of the disease.
The medication is administered via intravenous infusion and is most effective when given at the onset of symptoms. Treatment must be carried out under the supervision of a specialist experienced in rare metabolic diseases.
Common side effects include phlebitis at the infusion site, nausea, and abdominal pain. In rare cases, severe allergic reactions may occur, and patients should be closely monitored.
Human hemin is an essential therapeutic option for patients with acute porphyria, helping to reduce the severity and duration of acute episodes.